Avalo Therapeutics Net Income
| AVTX Stock | USD 14.64 0.63 4.50% |
As of the 10th of February, Avalo Therapeutics shows the mean deviation of 3.66, and Risk Adjusted Performance of (0.01). Avalo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Avalo Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 802.2952 | Revenue | Earnings Share (13.42) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -31.6 M | -33.2 M | |
| Net Loss | -31.6 M | -33.2 M | |
| Net Loss | -75.9 M | -72.1 M | |
| Net Loss | (3.89) | (4.08) | |
| Net Income Per E B T | 0.90 | 0.78 |
Avalo | Net Income | Build AI portfolio with Avalo Stock |
The evolution of Net Income for Avalo Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Avalo Therapeutics compares to historical norms and industry peers.
Latest Avalo Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Avalo Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Avalo Therapeutics financial statement analysis. It represents the amount of money remaining after all of Avalo Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Avalo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (35.13 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Avalo Net Income Regression Statistics
| Arithmetic Mean | (26,635,643) | |
| Geometric Mean | 22,291,247 | |
| Coefficient Of Variation | (85.51) | |
| Mean Deviation | 17,410,314 | |
| Median | (16,471,000) | |
| Standard Deviation | 22,775,651 | |
| Sample Variance | 518.7T | |
| Range | 96.2M | |
| R-Value | (0.55) | |
| Mean Square Error | 384.7T | |
| R-Squared | 0.30 | |
| Significance | 0.02 | |
| Slope | (2,490,057) | |
| Total Sum of Squares | 8299.7T |
Avalo Net Income History
Other Fundumenentals of Avalo Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Avalo Therapeutics Net Income component correlations
Avalo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Avalo Therapeutics is extremely important. It helps to project a fair market value of Avalo Stock properly, considering its historical fundamentals such as Net Income. Since Avalo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avalo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avalo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avalo Therapeutics. If investors know Avalo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avalo Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (13.42) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets | Return On Equity |
The market value of Avalo Therapeutics is measured differently than its book value, which is the value of Avalo that is recorded on the company's balance sheet. Investors also form their own opinion of Avalo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avalo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avalo Therapeutics' market value can be influenced by many factors that don't directly affect Avalo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Avalo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Avalo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Avalo Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Avalo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Avalo Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Avalo Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Avalo Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Avalo Therapeutics or generate 0.0% return on investment in Avalo Therapeutics over 90 days. Avalo Therapeutics is related to or competes with Prelude Therapeutics, Inventiva, Eupraxia Pharmaceuticals, Caribou Biosciences, Coherus BioSciences, Orchestra BioMed, and Aardvark Therapeutics. Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted ... More
Avalo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Avalo Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Avalo Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 23.4 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 6.93 |
Avalo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avalo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Avalo Therapeutics' standard deviation. In reality, there are many statistical measures that can use Avalo Therapeutics historical prices to predict the future Avalo Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.17) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Avalo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Avalo Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 3.66 | |||
| Coefficient Of Variation | (4,514) | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.62 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 23.4 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 6.93 | |||
| Skewness | 0.1044 | |||
| Kurtosis | 0.2085 |
Avalo Therapeutics Backtested Returns
Avalo Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0101, which signifies that the company had a -0.0101 % return per unit of standard deviation over the last 3 months. Avalo Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Avalo Therapeutics' mean deviation of 3.66, and Risk Adjusted Performance of (0.01) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.67, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Avalo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Avalo Therapeutics is expected to be smaller as well. At this point, Avalo Therapeutics has a negative expected return of -0.0482%. Please make sure to confirm Avalo Therapeutics' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if Avalo Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.53 |
Good reverse predictability
Avalo Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Avalo Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Avalo Therapeutics price movement. The serial correlation of -0.53 indicates that about 53.0% of current Avalo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.53 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 1.51 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Avalo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Avalo Therapeutics reported net income of (35.13 Million). This is 110.29% lower than that of the Biotechnology sector and 150.15% lower than that of the Health Care industry. The net income for all United States stocks is 106.15% higher than that of the company.
Avalo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avalo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics of similar companies.Avalo Therapeutics is currently under evaluation in net income category among its peers.
Avalo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avalo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avalo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Avalo Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Avalo Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Avalo Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avalo Therapeutics' value.| Shares | Blackrock Inc | 2025-06-30 | 155.9 K | Velan Capital Investment Management Lp | 2025-06-30 | 155 K | Perceptive Advisors Llc | 2025-06-30 | 139.7 K | Geode Capital Management, Llc | 2025-06-30 | 110.5 K | Adar1 Capital Management Llc | 2025-06-30 | 104.7 K | Ubs Group Ag | 2025-06-30 | 83.7 K | Sio Capital Management, Llc | 2025-06-30 | 72.2 K | Ikarian Capital, Llc | 2025-06-30 | 35.3 K | Northern Trust Corp | 2025-06-30 | 22.7 K | Bvf Inc | 2025-06-30 | 1 M | Nantahala Capital Management, Llc | 2025-06-30 | 995 K |
Avalo Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (346.32) % | ||||
| Current Valuation | 154.04 M | ||||
| Shares Outstanding | 18.51 M | ||||
| Shares Owned By Insiders | 3.48 % | ||||
| Shares Owned By Institutions | 99.21 % | ||||
| Number Of Shares Shorted | 2.98 M | ||||
| Price To Book | 2.90 X | ||||
| Price To Sales | 1,368 X | ||||
| Revenue | 441 K | ||||
| Gross Profit | (31.91 M) | ||||
| EBITDA | (68.34 M) | ||||
| Net Income | (35.13 M) | ||||
| Cash And Equivalents | 11.25 M | ||||
| Cash Per Share | 1.20 X | ||||
| Total Debt | 568 K | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 5.13 X | ||||
| Cash Flow From Operations | (49.06 M) | ||||
| Short Ratio | 9.54 X | ||||
| Earnings Per Share | (13.42) X | ||||
| Target Price | 36.11 | ||||
| Number Of Employees | 23 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 262.7 M | ||||
| Total Asset | 150.73 M | ||||
| Retained Earnings | (370.26 M) | ||||
| Working Capital | 131.93 M | ||||
| Net Asset | 150.73 M |
About Avalo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avalo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.